Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Bullboard Posts
Comment by GPLPPLon Dec 18, 2017 8:29pm
181 Views
Post# 27183336

RE:RE:Chinese investors are involed - sky rocket soon

RE:RE:Chinese investors are involed - sky rocket soon
On December 7th, 2017, Jenex presented its InterceptCS technology for cold sores and its TherOZap technology, currently being tested to inactivate the Zika virus, at the Chinese Global Financial Forum along with the proposed medical device target acquisitions for acne and other cosmetic applications Read more at https://www.stockhouse.com/news/press-releases/2017/12/12/the-jenex-corporation-announces-graduation-to-the-tsx-venture-update-on-chinese#l7iga22MLXhrHUWS.99 Please read between the lines .... We have to present our results to Chinese investors ... if you have bad news, you will present them to investors ... I have my answer ...
Bullboard Posts